Related Experiment Video
Updated: Jun 1, 2026
Isolation of Cerebral Capillaries from Fresh Human Brain Tissue
Published on: September 12, 2018
Beta-Amyloid Downregulates MDR1-P-Glycoprotein (Abcb1) Expression at the Blood-Brain Barrier in Mice
Anja Brenn1, Markus Grube, Michele Peters
1Department of Neuropathology, Institute of Pathology, University of Greifswald, 17487 Greifswald, Germany.
Abstract:
Neurovascular dysfunction is an important component of Alzheimer's disease, leading to reduced clearance across the blood-brain barrier and accumulation of neurotoxic β-amyloid (Aβ) peptides in the brain. It has been shown that the ABC transport protein P-glycoprotein (P-gp, ABCB1) is involved in the export of Aβ from the brain into the blood. To determine whether Aβ influences the expression of key Aβ transporters, we studied the effects of 1-day subcutaneous Aβ1-40 and Aβ1-42 administration via Alzet mini-osmotic pumps on P-gp, BCRP, LRP1, and RAGE expression in the brain of 90-day-old male FVB mice. Our results demonstrate significantly reduced P-gp, LRP1, and RAGE mRNA expression in mice treated with Aβ1-42 compared to controls, while BCRP expression was not affected. The expression of the four proteins was unchanged in mice treated with Aβ1-40 or reverse-sequence peptides. These findings indicate that, in addition to the age-related decrease of P-gp expression, Aβ1-42 itself downregulates the expression of P-gp and other Aβ-transporters, which could exacerbate the intracerebral accumulation of Aβ and thereby accelerate neurodegeneration in Alzheimer's disease and cerebral β-amyloid angiopathy.
Insights
Alzheimer's disease involves neurovascular dysfunction. This study shows that beta-amyloid 1-42 (Aβ1-42) peptides reduce the expression of key brain transporters, potentially worsening Aβ accumulation and neurodegeneration.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Neurovascular dysfunction and impaired blood-brain barrier (BBB) clearance contribute to Alzheimer's disease (AD) pathogenesis.
- P-glycoprotein (P-gp) is a key transporter protein responsible for exporting neurotoxic beta-amyloid (Aβ) peptides from the brain.
- Understanding how Aβ affects transporter expression is crucial for developing AD therapies.
Purpose of the Study:
- To investigate the impact of Aβ peptide administration on the expression of essential Aβ transporters in the brain.
- To determine if specific Aβ isoforms (Aβ1-40, Aβ1-42) differentially regulate transporter gene expression.
Main Methods:
- Administration of Aβ1-40 and Aβ1-42 peptides to 90-day-old male FVB mice using Alzet mini-osmotic pumps for 1 day.
- Quantitative analysis of mRNA expression levels for P-gp (ABCB1), BCRP, LRP1, and RAGE in mouse brain tissue.
- Comparison of transporter expression between Aβ-treated groups and control groups.
Main Results:
- Aβ1-42 treatment significantly downregulated the mRNA expression of P-gp, LRP1, and RAGE in the brain.
- BCRP expression remained unaffected by Aβ1-42 administration.
- Neither Aβ1-40 nor reverse-sequence peptides altered the expression of the studied transporters.
Conclusions:
- Aβ1-42 peptides, beyond age-related decline, actively downregulate P-gp and other Aβ-related transporters in the brain.
- This downregulation by Aβ1-42 may exacerbate intracerebral Aβ accumulation.
- The findings suggest a self-perpetuating mechanism that accelerates neurodegeneration in Alzheimer's disease and cerebral amyloid angiopathy.
